Auvelity becomes first non-antipsychotic approved for Alzheimer’s agitation
On 30 April 2026, Axsome Therapeutics announced the FDA approval of Auvelity (dextromethorphan + bupropion) for the treatment of agitation…
Central Nervous System
-
-
Corcept’s ALS drug demonstrates two-year benefit despite primary endpoint miss
Corcept Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has shown two-year survival benefit above placebo, despite the trial having failed to…
-
AAN 2026: New data demonstrates Symbravo’s cumulative benefit for acute migraine
On 21 April, at the 2026 American Academy of Neurology (AAN) meeting, during a poster session, Axsome Therapeutics presented results…
-
AAN 2026: Solengepras demonstrates emerging benefit in early Parkinson’s disease
At the American Academy of Neurology (AAN) 2026 annual conference, Cerevance reported findings from the Phase II ASCEND (NCT06006247) trial…
-
AAN 2026: BlueRock reports positive safety data for bemdaneprocel in Parkinson’s
On 21 April, at the 2026 American Academy of Neurology (AAN) meeting, BlueRock Therapeutics, a wholly owned, independently operated subsidiary…
-
AAN 2026: Phase I/II success for rese-cel in gMG signals potential amid competition
On April 20, at the 2026 American Academy of Neurology (AAN) meeting, Cabaletta Bio announced positive results from the Phase…
-
AAN 2026: new Vyvgart data show disease control in seronegative gMG
On 20 April, at the 2026 American Academy of Neurology (AAN) meeting, Argenx announced positive results from the Phase III,…
-
AAN 2026: frexalimab Phase II OLE data bolsters progressive MS ambitions
On 20 April, at the American Academy of Neurology (AAN) 2026 Annual Meeting, Sanofi presented three-year data from the open-label…
-
AAN 2026: Phase III success for azetukalner in focal epilepsy paves approval path
On 19 April, at the 2026 American Academy of Neurology (AAN) meeting, in the late-breaking science session, Xenon Pharmaceuticals announced…
-
UK launches programme to improve dementia clinical trial enrolment
An initiative to boost dementia clinical trial participation has been launched in the UK. The Dementia Trials Accelerator (DTA) has…
